Harriet de Wit, Ph.D.
Professor of Psychiatry; Director, Human Behavioral Pharmacology Laboratory, University of Chicago
One of the most rigorous behavioral pharmacologists studying psilocybin and MDMA — her human laboratory studies isolate the specific effects of psychedelic compounds on mood, cognition, and social behavior using controlled experimental designs.
Biography
Harriet de Wit is a professor of psychiatry and the director of the Human Behavioral Pharmacology Laboratory at the University of Chicago, where she has spent decades conducting some of the most methodologically rigorous human pharmacology studies in the field. Her laboratory specializes in controlled experimental designs — acute administration studies in carefully screened healthy volunteers — that isolate the specific behavioral and psychological effects of psychoactive compounds.
De Wit's work on psilocybin has examined its acute effects on mood, social cognition, and the specific behavioral mechanisms through which it may produce therapeutic change. Her controlled experimental approach provides a different and essential complement to the clinical trial methodology dominant in the psychedelic research field: rather than measuring outcomes weeks or months after treatment, her laboratory studies measure what psilocybin actually does to cognition, social behavior, and mood in real time, providing mechanistic understanding of how the compound works.
She has also conducted landmark MDMA human pharmacology studies, examining how MDMA affects social cognition, empathy, and interpersonal trust — the mechanisms likely underlying its therapeutic effectiveness for PTSD. Her work on MDMA's prosocial effects has contributed to understanding why MDMA-assisted therapy may be particularly effective for trauma that occurred in social contexts.
De Wit has trained numerous researchers in human behavioral pharmacology who have gone on to careers in the psychedelic research field, and her methodological standards have influenced how the broader field designs acute administration studies. She is a respected voice for experimental rigor in a field that is sometimes criticized for methodological shortcuts.
Organizations
Why They Matter to the LearnShrooms Community
Mechanistic human laboratory research — not just clinical outcome trials — is essential for understanding why psychedelic therapies work and for whom. De Wit's behavioral pharmacology studies provide the acute-effects data that complement the longer-term outcome studies from Hopkins, NYU, and MAPS, and her methodological rigor raises the evidentiary standard for the field.
Legal Context
For the legal landscape where Harriet de Wit, Ph.D. operates, see psilocybin laws in Illinois.